The most telling sign of neurological disease often isn't found in the brain. It's in the eye. For patients with conditions like multiple sclerosis or Alzheimer's, the retina can show signs of inflammation and degeneration years before other symptoms appear. But the gold-standard tool to see it, an optical coherence tomography (OCT) machine, is a bulky, expensive fixture in a specialist's office, not a tool for frequent, remote monitoring. That gap, between a powerful biomarker and the clinical workflow it could inform, is where JuneBrain has planted its flag.
The Maryland-based startup, founded in 2017 by neuroscientist and engineer Samantha Scott, is developing Neuro-i. It's a wearable, AI-powered retinal imaging system designed to bring OCT out of the ophthalmology clinic and into neurology offices, primary care, and even patients' homes [SEC, Unknown]. The bet is that by making high-resolution retinal scans portable and remote, clinicians can track disease progression and treatment response with a frequency that was previously impossible. For Scott, who was diagnosed with the neuromuscular disorder myasthenia gravis, the mission is viscerally personal [USC Viterbi School of Engineering, April 2023].
The clinical wedge: from the eye to the brain
JuneBrain's strategic wedge is a dual focus. While many digital health tools target either ophthalmology or neurology, Neuro-i is built for both. The device captures the detailed retinal layers that eye doctors need to diagnose conditions like glaucoma or macular degeneration. Simultaneously, its AI software is trained to look for specific signatures,thinning of the retinal nerve fiber layer, for instance,that are known biomarkers for neuroinflammatory and neurodegenerative diseases [New Orleans BioInnovation Center, 2026].
This positions the company at a unique intersection. Its reported $4.7 million sales pipeline is said to come from top neurology and eye care clinics, suggesting both specialties see potential utility [Gust, Unknown]. For neurologists managing complex, progressive diseases, a quantitative, objective measure of disease activity that doesn't require an MRI could be transformative. The standard of care today often relies on subjective clinical exams and patient-reported outcomes, with expensive imaging reserved for major diagnostic moments or suspected relapses.
A founder's diagnosis and a pre-FDA path
The company's trajectory is deeply intertwined with its founder's experience. Samantha Scott's background in neuroscience and engineering at USC Viterbi provided the technical foundation [USC Viterbi School of Engineering, April 2023]. Her diagnosis with myasthenia gravis, a chronic autoimmune condition that causes muscle weakness, supplied the patient's perspective and the driving urgency. In a 2023 interview, Scott stated the company was pre-FDA clearance, with a minimum viable product completed and "one step away" from design freeze and pivotal testing [YouTube, 2023].
This regulatory path is the company's most immediate and critical hurdle. Bringing a novel medical device to market requires navigating the FDA's 510(k) or De Novo pathways, a process that demands rigorous clinical data, substantial capital, and time. JuneBrain's ability to secure that clearance will be the definitive gate for its commercial ambitions.
Funding and the road to a pivotal trial
To finance that journey, JuneBrain has raised a seed round from a consortium of strategic and non-dilutive sources. The lead investor is TEDCO, Maryland's state-backed economic development corporation, which invested $250,000 in October 2025 and participated in an additional undisclosed seed round earlier that year [TEDCO, Oct 2025] [TEDCO, Jan 2025]. Other backers include the Medical Device Innovation Consortium and the National Science Foundation, indicating grant-based support for its R&D phase.
The company's investor base is a mix of regional economic development funds, medical device consortiums, and angel networks.
| Investor | Type | Note |
|---|---|---|
| TEDCO | State Economic Development | Lead seed investor [TEDCO, Jan 2025]. |
| Medical Device Innovation Consortium (MDIC) | Public-Private Partnership | Focus on advancing medical device regulatory science. |
| National Science Foundation (NSF) | Government Grant Agency | Non-dilutive research funding. |
| Springboard Enterprises | Investor Network | Focus on women-led businesses. |
| Silicon Valley Social Venture Fund | Philanthropic VC | Blends investment with social impact. |
This capital structure, leaning on non-dilutive grants and strategic partners, is a common early-stage medtech playbook. It allows a small team,reported at around 7-8 full-time employees [LinkedIn, 2026] [RocketReach, 2026],to extend its runway while de-risking the technology ahead of a larger, institutional venture round that would likely follow a successful FDA submission.
The competitive and execution landscape
The field of AI-powered diagnostic and monitoring tools is crowded, but JuneBrain's hardware-plus-software approach in neurology is more specialized. Its competitors include companies like Digital Diagnostics (formerly IDx), which has FDA clearance for autonomous AI diagnosis of diabetic retinopathy, and AEYE Health, which also uses retinal imaging for disease detection. The differentiation claim rests on wearability and the specific focus on neurological biomarkers.
The risks to the company's thesis are substantial and come in three distinct layers:
- Regulatory timing. The path to FDA clearance is long and uncertain. Any significant delays or requests for additional data could strain the company's financial and operational resources.
- Clinical adoption. Even with clearance, convincing neurologists to integrate a new hardware device and data stream into their practice represents a significant behavioral change. The value proposition must be overwhelmingly clear.
- Commercial scaling. As a hardware company, JuneBrain will eventually need to master manufacturing, inventory, logistics, and support at scale, a different operational challenge than a pure software play.
The company's answer to these risks appears to be its early commercial pipeline work and strategic partnerships. By engaging with clinics during the development phase, it aims to build a cohort of early adopters who are invested in the product's success, potentially smoothing the path to clinical integration.
The patient at the center
For all the talk of biomarkers and pipelines, the core of JuneBrain's proposition is a specific patient population: individuals living with chronic, progressive neurological diseases like multiple sclerosis, Alzheimer's, and Parkinson's. For them, the current standard of care involves episodic, in-person specialist visits. Monitoring is often reactive, triggered by a patient noticing a new or worsening symptom. This can mean delays in detecting a relapse or adjusting therapy, potentially leading to irreversible neurological damage.
A wearable device that allows for frequent, at-home scans could shift that paradigm toward proactive management. A neurologist could review quantitative retinal data during a telehealth visit, spotting subtle changes that precede clinical symptoms. For clinical trials, such a device could provide a continuous, objective endpoint, potentially reducing trial size and duration. The ambition is to give both patients and clinicians a window into disease activity that is currently shuttered, turning a rare, clinic-bound assessment into a routine part of chronic disease management.
The next twelve months for JuneBrain will be defined by its progress toward that pivotal FDA trial. The company must transition from a promising prototype to a locked-down device ready for rigorous clinical validation. Success on that front would not only unlock its reported pipeline but also position it as a pioneer in a new category of remote neuro-monitoring, proving that sometimes, the clearest view of the brain starts by looking elsewhere.
Sources
- [SEC, Unknown] Form C Filing | https://www.sec.gov/Archives/edgar/data/1911149/000174481823000003/jbrain.pdf
- [USC Viterbi School of Engineering, April 2023] Samantha Scott Profile | https://viterbischool.usc.edu/news/2023/04/meet-samantha-scott-founder-and-ceo-of-junebrain/
- [New Orleans BioInnovation Center, 2026] JuneBrain Company Profile | https://www.neworleansbio.com/portfolio/junebrain/
- [Gust, Unknown] JuneBrain Inc. Startup Profile | https://gust.com/companies/junebrain
- [YouTube, 2023] CEO Sam Scott Interview | https://www.youtube.com/watch?v=C1DWSR0n3YM
- [TEDCO, Oct 2025] TEDCO Invests in JuneBrain Press Release | https://www.tedcomd.com/news-events/press-releases/2025/tedco-invests-junebrain
- [TEDCO, Jan 2025] TEDCO Seed Investment | https://www.tedcomd.com
- [LinkedIn, 2026] JuneBrain Inc. Company Page | https://www.linkedin.com/company/junebrain
- [RocketReach, 2026] JuneBrain Inc. Management Team | https://rocketreach.co/junebrain-inc-management_b41305a9ff853efe